Established in 2016, the Institute is working to better understand the fundamental mechanisms used by immune cells to promote disease progression and response to treatment, developing and implementing novel technologies to better diagnose, prevent and guide the treatment of disease, and generating new therapies to modulate the immune system in a broad spectrum of diseases, including cancer, inflammatory, cardiovascular, and neurological diseases.
PrIISM is led by its Director, Miriam Merad, MD, PhD, Mount Sinai Professor in Cancer Immunology.